[HTML] nature.com

[HTML][HTML] Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

MS Gebre, S Rauch, N Roth, J Yu, A Chandrashekar… - Nature, 2022 - nature.com
Abstract The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in …
被引用次数：119 相关文章

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

MS Gebre, S Rauch, A Boon - 2021 - digitalcommons.wustl.edu
The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-
2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans 1. CV2CoV …

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

MS Gebre, S Rauch, N Roth, J Yu… - …, 2022 - ui.adsabs.harvard.edu
Abstract The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans …

Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine

MS Gebre, S Rauch, N Roth, J Yu, A Chandrashekar… - Nature, 2021 - cdr.lib.unc.edu
Abstract The CVnCoV (CureVac) mRNA vaccine for SARS-CoV-2 has recently been
evaluated in a phase 2b/3 efficacy trial in humans1. CV2CoV is a second-generation mRNA …

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

MS Gebre, S Rauch, N Roth, J Yu, A Chandrashekar… - Nature, 2022 - ideas.repec.org
The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-
2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans1. CV2CoV …

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

MS Gebre, S Rauch, N Roth, J Yu, A Chandrashekar… - Nature, 2022 - profiles.wustl.edu
Abstract The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans …

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

MS Gebre, S Rauch, N Roth, J Yu, A Chandrashekar… - Nature, 2022 - econpapers.repec.org
Abstract The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in …

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine.

MS Gebre, S Rauch, N Roth, J Yu, A Chandrashekar… - Nature, 2021 - europepmc.org
Abstract The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans …
[HTML] nih.gov

[HTML][HTML] Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

MS Gebre, S Rauch, N Roth, J Yu, A Chandrashekar… - Nature, 2022 - ncbi.nlm.nih.gov
Abstract The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans …

Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine

MS Gebre, S Rauch, N Roth, J Yu… - …, 2022 - pubmed.ncbi.nlm.nih.gov
The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-
2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans 1. CV2CoV …